Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.

Cardiovasc Diabetol · 2019 · PMC6714383 · PMID 31462224

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Alogliptin in the EXAMINE trial [ 25 ] showed a trend toward an increased risk for HF hospitalisation while sitagliptin in the TECOS trial showed no increased risk [ 23 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, the difference in overall mortality did not reach statistical significance (OR 0.83, 95% CI 0.68–1.02) in the CREDENCE trial [ 18 ], as with other trials on SGLT-2 inhibitors [ 14 , 15 ], which differed from the findings in the EMPA-REG OUTCOME trial [ 10 ] and this network meta-analysis.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.